{
  "id": 14458660,
  "title": "Why is Chemours stock sliding today?",
  "url": "https://urgent.news/2026/10/14/why-is-chemours-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T13:23:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-chemours-stock-sliding-today-93CH-4949452"
  },
  "original_language": "en",
  "account": "Chemours stock experienced a 2.3% decline in pre-market trading today following Mizuho's downgrade of the specialty chemicals company from Outperform to Neutral. The reduction in price target from $18 to $15 was driven by slower-than-expected earnings growth from next-generation refrigerants and concerns over the sustainability of the stabilization in titanium dioxide pigment markets. Mizuho argued that any recovery in TiO2 pricing was likely supported by temporary factors, such as trade restrictions and limited raw materials in China, rather than genuine demand improvements.\n\nRBC Capital's recent downgrade of Chemours to Sector Perform, coupled with a price target reduction from $22 to $14, further compounded the stock's decline. RBC cited persistent demand weakness in both titanium dioxide and related high-margin Thermal & Specialized Solutions projects, which are expected to extend headwinds through year-end. Additionally, the company's EBITDA estimates for the third quarter and fiscal years 2026 and 2027 were significantly lowered by RBC.\n\nThe downgrades come amid broader analyst caution surrounding Chemours. UBS had already lowered its price target to $16 earlier in October, while Goldman Sachs maintains a neutral stance on the stock. Over the past six months, Chemours shares have dropped more than 40% and are currently below their 52-week high of $28.67.\n\nThe broader U.S. equity market is also experiencing a slight downturn, with the S&P 500 down 0.3% and the Nasdaq falling 0.7% in pre-market trading. This overall market environment, combined with the company-specific selling pressure, has contributed to Chemours' stock falling closer to its 52-week low of $10.44, as investors reevaluate the pace and durability of the company's earnings recovery.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}